Jack Henry Kotnik

Jack Henry Kotnik

Auto-generated profile, based on publicly available information

Jack Henry Kotnik

Department of Bioengineering, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Science Advances
Verified
Journal Article
Open access
NPNuttada Panpradist
Nuttada Panpradist
EKEnos C. Kline
Enos C. Kline
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
QWQin Wang
Qin Wang
BLBarry Lutz
Barry Lutz
A unique four-plexed RT-LAMP test kit operated by health workers can provide faster, more sensitive results than laboratory tests.

22 February 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
RGRachel E Geyer
Rachel E Geyer
JKJack Henry Kotnik
Jack Henry Kotnik
VLVictoria Lyon
Victoria Lyon
EBElisabeth Brandstetter
Elisabeth Brandstetter
MSMonica Zigman Suchsland
Monica Zigman Suchsland
MTMatthew Thompson
Matthew Thompson
Background: Rapid diagnostic tests (RDTs) for influenza used by individuals at home could potentially expand access to testing and reduce the impact of influenza on health systems. Improving access to testing could lead to earlier diagnosis following symptom onset, allowing more rapid interventions for those who test positive, including behavioral changes to minimize spread. However, the accuracy of RDTs for influenza has not been determined in self-testing populations. Objective: This study aims to assess the accuracy of an influenza RDT conducted at home by lay users with acute respiratory illness compared with that of a self-collected sample by the same individual mailed to a laboratory for reference testing. Methods: We conducted a comparative accuracy study of an at-home influenza RDT (Ellume) in a convenience sample of individuals experiencing acute respiratory illness symptoms. Participants were enrolled in February and March 2020 from the Greater Seattle region in Washington, United States. Participants were mailed the influenza RDT and reference sample collection materials, which they completed and returned for quantitative reverse-transcription polymerase chain reaction influenza testing in a central laboratory. We explored the impact of age, influenza type, duration, and severity of symptoms on RDT accuracy and on cycle threshold for influenza virus and ribonuclease P, a marker of human DNA. Results: A total of 605 participants completed all study steps and were included in our analysis, of whom 87 (14.4%) tested positive for influenza by quantitative reverse-transcription polymerase chain reaction (70/87, 80% for influenza A and 17/87, 20% for influenza B). The overall sensitivity and specificity of the RDT compared with the reference test were 61% (95% CI 50%-71%) and 95% (95% CI 93%-97%), respectively. Among individuals with symptom onset ≤72 hours, sensitivity was 63% (95% CI 48%-76%) and specificity was 94% (95% CI 91%-97%), whereas, for those with duration >72 hours, sensitivity and specificity were 58% (95% CI 41%-74%) and 96% (95% CI 93%-98%), respectively. Viral load on reference swabs was negatively correlated with symptom onset, and quantities of the endogenous marker gene ribonuclease P did not differ among reference standard positive and negative groups, age groups, or influenza subtypes. The RDT did not have higher sensitivity or specificity among those who reported more severe illnesses. Conclusions: The sensitivity and specificity of the self-test were comparable with those of influenza RDTs used in clinical settings. False-negative self-test results were more common when the test was used after 72 hours of symptom onset but were not related to inadequate swab collection or severity of illness. Therefore, the deployment of home tests may provide a valuable tool to support the management of influenza and other respiratory infections.

13 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NPNuttada Panpradist
Nuttada Panpradist
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
EKEnos Kline
Enos Kline
QWQin Wang
Qin Wang
PDPaul K Drain
Paul K Drain
RNA amplification tests allow sensitive detection of SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed “Harmony COVID-19”, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device that processes up to 4 samples simultaneously. Our lyophilized reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect as little as 15 SARS-CoV-2 RNA copies per reaction, and it can report as early as 17 min for samples with high viral load (2 x 10 5 RNA copies per reaction). Analysis of RNA extracted from clinical nasal specimens (n = 101) showed 95% concordance with RT-PCR, including 100% specificity in specimens positive for other viruses and bacteria. Analysis of contrived samples in the nasal matrix showed detection of 92% or 100% in samples with ≥20 or ≥100 particles per reaction, respectively. Usability testing showed 95% accuracy by healthcare workers operating the test for the first time. ONE SENTENCE SUMMARY: Harmony COVID-19: point-of-care SARS-CoV-2 RNA detection

29 July 2023 in Analytica Chimica Acta
Verified
Journal Article
Closed access
QWQin Wang
Qin Wang
NPNuttada Panpradist
Nuttada Panpradist
JKJack Henry Kotnik
Jack Henry Kotnik
Richard C. WillsonRichard C. Willson
Richard C. Willson
KKKaterina Kourentzi
Katerina Kourentzi
JLJames J. Lai
James J. Lai

14 October 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
LRLauren E. Rylaarsdam
Lauren E. Rylaarsdam
BSBenjamin W. Skubi
Benjamin W. Skubi
RNRuth V. Nichols
Ruth V. Nichols
BOBrendan L. O’connell
Brendan L. O’connell
JKJack Henry Kotnik
Jack Henry Kotnik
AAAndrew C. Adey
Andrew C. Adey
Single-cell sequencing technologies have revolutionized biomedical research by enabling deconvolution of cell type-specific properties from heterogeneous tissue. While robust tools have been developed to handle bioinformatic challenges posed by single-cell RNA and ATAC data, options for emergent modalities such as methylation are limited, impeding the utility of results. Here we present Amethyst, a comprehensive R package for atlas-scale single-cell methylation sequencing data analysis. Amethyst begins with base-level methylation calls and enables clustering of distinct biological populations, cell type annotation, differentially methylated region calling, and interpretation of results - facilitating rapid data interaction in a local environment. We introduce the workflow using published single-cell methylation human peripheral blood mononuclear cell and cortex data. We further apply Amethyst to an atlas-scale brain dataset and deconvolute non-CG methylation patterns in human astrocytes and oligodendrocytes, challenging the notion that this form of methylation is principally relevant to neurons in the brain. Tools such as Amethyst will make single-cell methylation data analysis more accessible, catalyzing research progress across diverse contexts.

5 March 2021 in JMIR Preprints
Verified
Preprint
Open access
RGRachel E Geyer
Rachel E Geyer
JKJack Henry Kotnik
Jack Henry Kotnik
VLVictoria Lyon
Victoria Lyon
EBElisabeth Brandstetter
Elisabeth Brandstetter
MSMonica Zigman Suchsland
Monica Zigman Suchsland
MTMatthew Thompson
Matthew Thompson
BACKGROUND Rapid diagnostic tests (RDTs) for influenza used by individuals at home could potentially expand access to testing and reduce the impact of influenza on health systems. Improving access to testing could lead to earlier diagnosis following symptom onset, allowing more rapid interventions for those who test positive, including behavioral changes to minimize spread. However, the accuracy of RDTs for influenza has not been determined in self-testing populations. OBJECTIVE This study aims to assess the accuracy of an influenza RDT conducted at home by lay users with acute respiratory illness compared with that of a self-collected sample by the same individual mailed to a laboratory for reference testing. METHODS We conducted a comparative accuracy study of an at-home influenza RDT (Ellume) in a convenience sample of individuals experiencing acute respiratory illness symptoms. Participants were enrolled in February and March 2020 from the Greater Seattle region in Washington, United States. Participants were mailed the influenza RDT and reference sample collection materials, which they completed and returned for quantitative reverse-transcription polymerase chain reaction influenza testing in a central laboratory. We explored the impact of age, influenza type, duration, and severity of symptoms on RDT accuracy and on cycle threshold for influenza virus and ribonuclease P, a marker of human DNA. RESULTS A total of 605 participants completed all study steps and were included in our analysis, of whom 87 (14.4%) tested positive for influenza by quantitative reverse-transcription polymerase chain reaction (70/87, 80% for influenza A and 17/87, 20% for influenza B). The overall sensitivity and specificity of the RDT compared with the reference test were 61% (95% CI 50%-71%) and 95% (95% CI 93%-97%), respectively. Among individuals with symptom onset ≤72 hours, sensitivity was 63% (95% CI 48%-76%) and specificity was 94% (95% CI 91%-97%), whereas, for those with duration >72 hours, sensitivity and specificity were 58% (95% CI 41%-74%) and 96% (95% CI 93%-98%), respectively. Viral load on reference swabs was negatively correlated with symptom onset, and quantities of the endogenous marker gene ribonuclease P did not differ among reference standard positive and negative groups, age groups, or influenza subtypes. The RDT did not have higher sensitivity or specificity among those who reported more severe illnesses. CONCLUSIONS The sensitivity and specificity of the self-test were comparable with those of influenza RDTs used in clinical settings. False-negative self-test results were more common when the test was used after 72 hours of symptom onset but were not related to inadequate swab collection or severity of illness. Therefore, the deployment of home tests may provide a valuable tool to support the management of influenza and other respiratory infections.